文献速递血栓与止血

血浆微小RNA-145高水平与未来静脉血栓栓塞症风险降低相关:HUNT研究

High microRNA-145 plasma levels are associated with decreased risk of future incident venous thromboembolism: the HUNT study.
PubMed 文献 · Blood · 2024-01-01

在HUNT3人群队列的病例-队列研究中,510例静脉血栓栓塞症(VTE)病例与1890例子队列参与者按miR-145水平四分位分组,采用加权Cox回归分析。年龄和性别校正后,miR-145最高四分位组较最低四分位组VTE风险降低49%(HR 0.51,95%CI 0.38-0.68),无诱因VTE关联更明显(HR 0.39,95%CI 0.25-0.61);进一步校正BMI、基线癌症和动脉心血管疾病后风险估计基本不变。

要点

  • 血浆miR-145最高四分位组较最低四分位组VTE风险降低49%(HR 0.51,95%CI 0.38-0.68)。
  • 无诱因VTE的关联更明显(HR 0.39,95%CI 0.25-0.61)。
  • 进一步校正BMI、基线癌症和动脉心血管疾病后风险估计基本不变。

核心结论

  • 血浆miR-145表达水平升高与未来新发VTE风险降低相关。
  • miR-145对VTE的保护作用与既往实验数据一致,提示miR-145有潜力成为VTE预防的靶点。

研究设计与样本

  • 病例-队列研究,数据来自Trøndelag健康研究第三次调查(HUNT3)这一人群队列。
  • 纳入新发VTE病例510例和子队列1890例,基线血浆样本检测miR-145表达水平。
  • 按子队列参与者miR-145水平四分位分组,采用加权Cox回归估计风险比(HR)及95%置信区间(CI)。

主要发现

  • 年龄和性别校正分析中,miR-145最高四分位组较最低四分位组VTE风险降低49%(HR 0.51,95%CI 0.38-0.68)。
  • 无诱因VTE的负向关联最明显(HR 0.39,95%CI 0.25-0.61)。
  • 进一步校正基线BMI、癌症和动脉心血管疾病后,风险估计基本不变。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

MicroRNA-145 (miR-145) has been reported to downregulate the expression of tissue factor and factor XI in vitro and decrease venous thrombus formation in animal models. However, the association between miR-145 and risk of future venous thromboembolism (VTE) in the general population remains unknown. We investigated the association between plasma levels of miR-145 and risk of future VTE in a case-cohort study. Incident VTE cases (n = 510) and a subcohort (n = 1890) were derived from the third survey of the Trøndelag Health Study (HUNT3), a population-based cohort. The expression levels of miR-145 were measured in plasma samples obtained at baseline. The study population was divided into quartiles based on miR-145 levels in participants in the subcohort, and weighted Cox regression was used to estimate hazard ratios (HRs) with 95% confidence intervals (CIs). Plasma levels of miR-145 were inversely associated with VTE risk. Participants with miR-145 levels in the highest quartile had a 49% lower risk of VTE (HR, 0.51; 95% CI, 0.38-0.68) than those with miR-145 in the lowest quartile in age- and sex-adjusted analysis, and the inverse association was most pronounced for unprovoked VTE (HR, 0.39; 95% CI, 0.25-0.61). Risk estimates remained virtually the same after further adjustment for body mass index, and cancer and arterial cardiovascular disease at baseline. In conclusion, elevated expression levels of miR-145 in plasma were associated with decreased risk of future incident VTE. The protective role of miR-145 against VTE is consistent with previous experimental data and suggests that miR-145 has the potential to be a target for VTE prevention.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Morelli VM, Snir O, Hindberg KD, et al. High microRNA-145 plasma levels are associated with decreased risk of future incident venous thromboembolism: the HUNT study. Blood. 2024. PMID: 38211336. doi:10.1182/blood.2023022285

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。